(P078) Radiation Therapy in the Management of Carcinosarcoma of the Uterus

OncologyOncology Vol 29 No 4_Suppl_1
Volume 29
Issue 4_Suppl_1

Pelvic radiation reduces the risk of pelvic relapse in patients with MMMT and may be indicated with patients at high risk for pelvic recurrence, including patients with cervical involvement, heterologous elements, and stage III disease.

Jillian R. Gunther, MD, PhD, Eva N. Christensen, MD, PhD, Pamela K. Allen, PhD, Lois M. Ramondetta, MD, Anuja Jhingran, MD, Nicole D. Fleming, MD, Elizabeth Euscher, MD, Karen H. Lu, Patricia J. Eifel, MD, Ann H. Klopp, MD, PhD; UT MD Anderson Cancer Center; Radiation Oncology Associates

PURPOSE: Uterine mixed Müllerian tumor (MMMT) is often treated with multimodality therapy, including surgery, chemotherapy, vaginal cuff brachytherapy (VCB), and/or pelvic radiation. However, the indications for pelvic and vaginal cuff radiation are unclear. To investigate this, we reviewed our institutional experience with treatment of uterine MMMT.

METHODS: We performed a retrospective review of 155 women with stage I–III uterine carcinosarcoma who underwent total abdominal hysterectomy-bilateral salpingo-oophorectomy (TAH-BSO) at our institution between 1990 and 2011. Overall survival (OS), disease-specific survival (DSS), and pelvic relapse–free survival (PRFS) were calculated using the Kaplan-Meier method, with differences assessed using a log-rank test. Multivariate Cox proportional hazards regression analyses were performed to evaluate the influence of different factors on DSS and PRFS.

RESULTS: The study included patients with stage I (n = 98), II (n = 11), and III (n = 46) uterine MMMT. Median follow-up was 51 months (range: 2–278 mo). A total of 70 patients (45%) received chemotherapy (21 concurrent, 58 adjuvant, 9 both). Also, 108 patients (70%) received radiation therapy (RT); 35% of these patients received pelvic radiation, and 65% received pelvic radiation with or without additional brachytherapy. The 5-year OS for all patients was 48.6% (stage I, 53.8%; II, 30.0%; and III, 42.5%). The 5-year DSS was 57.17% (stage I, 60.88%; II, 44.44%; and III, 51.82%). The first site of recurrence was in the pelvis and/or para-aortic (PA) lymph nodes for 28 patients (44%), abdomen ± pelvis for 13 patients (21%), and distant for 22 patients (35%). On univariate analysis, lower rates of DSS were seen in patients aged ≥ 65 years (P = .001) and with hypertension (P = .03), higher tumor grade (P = .02), cervical involvement (P = .001), and lymphovascular space invasion (LVSI) (P = .004). On multivariate analysis, age ≥ 65 years (P = .001), cervical involvement (P = .03), and LVSI (P = .01) remained independently associated with lower DSS.

PRFS was higher in patients receiving pelvic radiation as compared with VCB or no radiation (88.3% at 5 yr for pelvic radiation vs 67.4% for VCB and 71.2% for no RT; P = .04). Among patients who did not receive pelvic radiation, cervical involvement (hazard ratio [HR] = 3.2; P = .03) and heterologous elements (HR = 2.9; P = .04) were associated with pelvic relapse. In stage III patients, pelvic radiation was associated with higher rates of 5-year PRFS (90.0% vs 55.5%; P = .046), DSS (64.6% vs 46.4%; P = .13) and OS (64.6% vs 34.0%; P = .04). 

CONCLUSIONS: Pelvic radiation reduces the risk of pelvic relapse in patients with MMMT and may be indicated with patients at high risk for pelvic recurrence, including patients with cervical involvement, heterologous elements, and stage III disease.

Proceedings of the 97th Annual Meeting of the American Radium Society- americanradiumsociety.org

Articles in this issue

(P005) Ultrasensitive PSA Identifies Patients With Organ-Confined Prostate Cancer Requiring Postop Radiotherapy
(P001) Disparities in the Local Management of Breast Cancer in the United States According to Health Insurance Status
(P002) Predictors of CNS Disease in Metastatic Melanoma: Desmoplastic Subtype Associated With Higher Risk
(P003) Identification of Somatic Mutations Using Fine Needle Aspiration: Correlation With Clinical Outcomes in Patients With Locally Advanced Pancreatic Cancer
(P004) A Retrospective Study to Assess Disparities in the Utilization of Intensity-Modulated Radiotherapy (IMRT) and Proton Therapy (PT) in the Treatment of Prostate Cancer (PCa)
(S001) Tumor Control and Toxicity Outcomes for Head and Neck Cancer Patients Re-Treated With Intensity-Modulated Radiation Therapy (IMRT)-A Fifteen-Year Experience
(S003) Weekly IGRT Volumetric Response Analysis as a Predictive Tool for Locoregional Control in Head and Neck Cancer Radiotherapy 
(S004) Combination of Radiotherapy and Cetuximab for Aggressive, High-Risk Cutaneous Squamous Cell Cancer of the Head and Neck: A Propensity Score Analysis
(S005) Radiotherapy for Carcinoma of the Hypopharynx Over Five Decades: Experience at a Single Institution
(S002) Prognostic Value of Intraradiation Treatment FDG-PET Parameters in Locally Advanced Oropharyngeal Cancer
(P006) The Role of Sequential Imaging in Cervical Cancer Management
(P008) Pretreatment FDG Uptake of Nontarget Lung Tissue Correlates With Symptomatic Pneumonitis Following Stereotactic Ablative Radiotherapy (SABR)
(P009) Monte Carlo Dosimetry Evaluation of Lung Stereotactic Body Radiosurgery
(P010) Stereotactic Body Radiotherapy for Treatment of Adrenal Gland Metastasis: Toxicity, Outcomes, and Patterns of Failure
(P011) Stereotactic Radiosurgery and BRAF Inhibitor Therapy for Melanoma Brain Metastases Is Associated With Increased Risk for Radiation Necrosis
Related Videos
Additional analyses of patient-reported outcomes and MRD status in the QuANTUM-First trial are also ongoing, says Harry P. Erba, MD, PhD.
Investigators must continue to explore the space for lisocabtagene maraleucel in mantle cell lymphoma, according to Manali Kamdar, MD.
Those with CML should discuss adverse effects such as nausea or fatigue with their providers to help optimize their quality of life during treatment.
Patients with CML can become an active part of their treatment plan by discussing any questions that come to mind with their providers.
Jorge E. Cortes, MD, emphasizes proper communication between patients with chronic myeloid leukemia and their providers during the treatment course.
Dietary interventions or other medications may help mitigate diarrhea in patients who undergo therapy for chronic myeloid leukemia.
Whether CAR T-cell therapy or T-cell engagers should dominate the multiple myeloma landscape may be hard to determine, says David S. Siegel, MD.
Next steps for research in the multiple myeloma space may include the development of novel CAR T-cell strategies and bispecific antibodies.
Ongoing research may clarify the potential benefit of avelumab when administered in combination with other agents in advanced urothelial carcinoma.
Spatial analyses may help determine factors that influence responses to sacituzumab govitecan-containing regimens in urothelial carcinoma.
Related Content